February 2025 – Page 16

Bristol Myers Squibb Expands Cost-Cutting Measures and Streamlines Pipeline for Future Growth

3 months ago talkbio0Tagged cost-cutting, Drug Industry, Efficiency, Myers, operational, Optimization, pipeline, restructuring, squibb, strategic

Bristol Myers Squibb, cost-cutting, pipeline optimization, patent cliff, strategic restructuring, operational efficiency, pharmaceutical industry

Congressional Healthcare Reform Priorities Under Trump’s Second Term

3 months ago talkbio0Tagged Alcohol abuse, Medicaid block grants, Medicare, Prices, repeal, Translucent, Value-Based Care

ACA repeal, Medicaid block grants, price transparency, Medicare Advantage, drug pricing, value-based care

LinusBio Introduces ClearStrand-ASD: Revolutionary Autism Diagnostic Aid Using Hair Analysis

3 months ago talkbio0Tagged Autistic Disorder, biomarker test, ClearStrand-ASD, Detection, Diagnosis, Exposome, Hair Analysis, LinusBio, Negative Predictive Value of Diagnostic Test

LinusBio, ClearStrand-ASD, autism diagnostic, hair analysis, biomarker test, early detection, negative predictive value, exposome medicine

DOGE Access to Treasury Systems Restricted Amid Concerns Over CMS Scrutiny

3 months ago talkbio0Tagged concerns, DOGE, Elon, federal, Musk secretion from Musk Deer, Myasthenic Syndromes, Congenital, Patient location type - Department, payment, Privacy

Elon Musk, DOGE, Treasury Department, CMS, payment systems, privacy concerns, lawsuit, federal court order

Eli Lilly Streamlines Pipeline, Removing Alzheimer’s and Obesity Candidates in Q4 2024

3 months ago talkbio0Tagged Alzheimer 's disease, Ceperognastat, Clinical Trials, Drug Development, Eli, Eli Lilly, Obesity, pipeline update

Eli Lilly, pipeline update, Alzheimer’s disease, obesity, ceperognastat, clinical trials, drug development

Kura Oncology and Kyowa Kirin Report Positive Phase 2 Results for Ziftomenib in AML, Prepare for FDA Submission

3 months ago talkbio0Tagged Kirin, KOMET-001, Kura Oncology, Kyowa, Leukemia, Myelocytic, Acute, NPM1, NPM1-mutant, Phase 2 trial, Submission, United States Food and Drug Administration, Ziftomenib

Ziftomenib, AML, NPM1-mutant, Phase 2 trial, KOMET-001, FDA submission, Kura Oncology, Kyowa Kirin

Viracta Therapeutics Shuts Down Operations, Lays Off Entire Workforce

3 months ago talkbio0Tagged biotech closure, financial troubles, Nasdaq, oncology company, strategic alternatives, wind-down operations, workforce termination

biotech closure, oncology company, financial troubles, workforce termination, wind-down operations, Nasdaq delisting, strategic alternatives

Pfizer Appoints Jeffrey Legos as New Chief Oncology Officer, Bolstering Cancer Drug Development Efforts

3 months ago talkbio0Tagged Antineoplastic Agents, Appointments, Drug Industry, Jeffrey, Leadership, Legos, Neoplasms, Novartis, Pfizer

Pfizer, Jeffrey Legos, oncology, cancer drug development, pharmaceutical industry, Novartis, leadership appointment

U.S. Hospitals Urge Trump to Exempt Medical Supplies and Pharmaceuticals from New Tariffs

3 months ago talkbio0Tagged Canada, chain disruption, China, Health care facility, medical supplies, Mexico, patient safety, tariffs

Tariffs, medical supplies, pharmaceuticals, American Hospital Association, China, Mexico, Canada, healthcare costs, supply chain disruption, patient safety

EyePoint Pharmaceuticals Reports Positive Phase 2 Results for DURAVYU in Wet AMD, Challenging Established Anti-VEGF Therapies

3 months ago talkbio0Tagged AMD, anti-VEGF therapy, Clinical Trials, DURAVYU, EyePoint Pharmaceuticals, Glycogen storage disease type II, Movement, Prices, vorolanib

DURAVYU, vorolanib, wet AMD, anti-VEGF therapy, EyePoint Pharmaceuticals, clinical trial results, stock price movement